GLP-1 medications expand use in obesity and lifespan research

Claims

What the coverage asserts, and how many sources carry each claim.

• [● 3 SOURCES] Semaglutide treatment in mice reduced calorie intake by 24%. www.diepresse.com · www.ad-hoc-news.de · offthepress.com
• [● 8 SOURCES] Common side effects of GLP-1 medications include nausea, constipation, and a feeling of fullness. www.halternerzeitung.de · www.leinetal24.de · www.marler-zeitung.de · www.europeonline-magazine.eu · www.hellwegeranzeiger.de · +1 more
• [○ 1 SOURCE] Patients using a 0.25 mg dose of injectable semaglutide for at least six months saw an average weight reduction of 2.2% after one year. www.doctor33.it
• [● 3 SOURCES] Semaglutide treatment in aged mice increased median lifespan from 742 to 834 days, an increase of approximately 12%. www.diepresse.com · www.ad-hoc-news.de · offthepress.com
• [● 3 SOURCES] Weekly costs for Wegovy or Mounjaro injections in Germany range between 43 and 122 euros. www.ruhrnachrichten.de · www.saarbruecker-zeitung.de
• [○ 1 SOURCE] An observational study found a higher frequency of alopecia among type 2 diabetes patients treated with GLP-1 receptor agonists. www.vanityfair.it
• [○ 1 SOURCE] GLP-1 medications show measurable pharmacological effects even at doses lower than standard maintenance levels. www.doctor33.it
• [○ 1 SOURCE] Patients using a 2.5 mg dose of tirzepatide for at least six months saw an average weight reduction of 5.5% after one year. www.doctor33.it
• [● 4 SOURCES] Psychiatrists warn that GLP-1 medications may pose risks to individuals with undiagnosed mental health conditions or eating disorders. www.knysnaplettherald.com · www.mosselbayadvertiser.com · www.oudtshoorncourant.com · www.suidkaapforum.com
• [○ 1 SOURCE] Patients using initial doses of semaglutide and tirzepatide for six months saw average weight reductions of 2.2% and 5.5% respectively after one year. www.doctor33.it
• [○ 1 SOURCE] Semaglutide use was associated with a 21% lower risk of psychiatric hospitalization in certain bipolar patients. www.mundonow.com
• [○ 1 SOURCE] GLP-1 medications may reduce cravings for alcohol and nicotine by interacting with brain reward pathways. world-today-journal.com